The International Diabetes Federation (IDF) and the Association of Mobile Operators GSMA, have launched the Mhealth Grand Tour project, a bicycle tour through 5 countries starring a team of 70 people with diabetes, and born with the targetto raise awareness about diabetes disease and the benefits provided by information and communication technologies in their treatment and control.
The Mhealth Grand Tour, with an planlast stage.
One of the leading teams is the Team Blood Glucose team, composed of 20 cyclists with diabetes, sponsorized by Emminens Econecta de Roche Diagnostics.
Pathology control thanks to the Emminens Econecta technological platform
The glycemic state control of four of the TEAM BG runners will be carried out at the end of each stage, thanks to the sending of their data online through ACCU-Chek technology and the Emminens technological platform Econecta to Dr. Cintia González, Endocrinology specialist at the Hospital de la Santa Creu and Sant Pau in Barcelona and Ciber-BBN, and coordinator of the New Technology Working Group of the Spanish Diabetes Society, and Serafín Murillo, Cyberdem Nutritionist.Thanks to this technology, specialists will be able to control their blood glucose levels at a distance and adapt their treatment on the next day.
"Telemedicine allows in most cases a more frequent contact with the patient, improving motivation and adhesion to treatment, and therefore the control of the disease," says Dr. González.
And it is that the potentiality of the Internet, mobile communications, portable devices and all types of electronic instrumentation in the development of E-Salud services is very important, also for those cases, such as the MHEALTH GRAD TOUR, where to carry a correct monitoring and monitoringof patients is a necessity.
Emminens Econecta is a web solution designed to offer a comprehensive diabetes management service for both patients and health professionals.Its safe and confidential information exchange system unifies in a single technological platform the analysis and compilation of glycemia, insulin and other clinical parameters to monitor diabetes in the historical.
Time saving and costs for both the patient and the medical professional and the health authorities, including a lower loss of working days for the patient, greater agility in therapeutic decision making to improve patient therapy and aGreater adhesion to treatment thanks to a more personal and frequent contact, are some of the reasons that make Emminens econecta an alternative with great potential and a great complement to the health care of the patient with diabetes of the future.
Buchanan has encouraged "all people with diabetes to get involved with new technologies and tools that can help us have a better, healthier and more safe life. Emminens Econecta can only help."He also added that "we have already seen the invaluable help we give us (new technologies) in other areas of our life. It is time for the world of health to also update."